Selenomethionine and methyl selenocysteine

Multiple-dose pharmacokinetics in selenium-replete men

James R. Marshall, Raymond F. Burk, Rochelle Payne Ondracek, Kristina E. Hill, Marjorie Perloff, Warren Davis, Roberto Pili, Saby George, Raymond Bergan

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

According to the Nutritional Prevention of Cancer (NPC) trial, a selenized yeast supplement containing selenium, 200 mcg/day, decreased the incidence of total cancer, cancers of the prostate, colon and lung, and cancer mortality. The active agent in the selenized yeast supplement was assumed to be selenomethionine (SEMET), although the supplement had not been well speciated. The SELECT study, largely motivated by the NPC trial, enrolling nearly 40 times as many subjects, showed unequivocally that selenium 200 mcg/day, with selenium in the form of SEMET, does not protect selenium-replete men against prostate or other major cancer. The agent tested by SELECT, pure SEMET, could have been different from the selenized yeast tested in NPC. One of the selenium forms suspected of having chemopreventive effects, and which may have been present in the NPC agent, is methyl selenocysteine (MSC). This study, with 29 selenium-replete patients enrolled in a randomized, double-blind trial, compared the multiple-dose toxicity, pharmacokinetics and pharmacodynamics of MSC and SEMET. Patients were on trial for 84 days. No toxicity was observed. Although SEMET supplementation increased blood selenium concentration more than MSC did, neither form had a more than minimal impact on the two major selenoproteins: selenoprotein P(SEPP1) and glutathione peroxidase(GPX).

Original languageEnglish (US)
Pages (from-to)26312-26322
Number of pages11
JournalOncotarget
Volume8
Issue number16
DOIs
StatePublished - 2017

Fingerprint

Selenomethionine
Selenium
Pharmacokinetics
Neoplasms
Yeasts
Colonic Neoplasms
Lung Neoplasms
Selenoprotein P
Selenoproteins
Glutathione Peroxidase
selenomethylselenocysteine
Prostate
Prostatic Neoplasms
Mortality
Incidence

Keywords

  • Chemoprevention
  • Methyl selenocysteine
  • Pharmacokinetics
  • Selenium
  • Selenomethionine

ASJC Scopus subject areas

  • Oncology

Cite this

Marshall, J. R., Burk, R. F., Ondracek, R. P., Hill, K. E., Perloff, M., Davis, W., ... Bergan, R. (2017). Selenomethionine and methyl selenocysteine: Multiple-dose pharmacokinetics in selenium-replete men. Oncotarget, 8(16), 26312-26322. https://doi.org/10.18632/oncotarget.15460

Selenomethionine and methyl selenocysteine : Multiple-dose pharmacokinetics in selenium-replete men. / Marshall, James R.; Burk, Raymond F.; Ondracek, Rochelle Payne; Hill, Kristina E.; Perloff, Marjorie; Davis, Warren; Pili, Roberto; George, Saby; Bergan, Raymond.

In: Oncotarget, Vol. 8, No. 16, 2017, p. 26312-26322.

Research output: Contribution to journalArticle

Marshall, JR, Burk, RF, Ondracek, RP, Hill, KE, Perloff, M, Davis, W, Pili, R, George, S & Bergan, R 2017, 'Selenomethionine and methyl selenocysteine: Multiple-dose pharmacokinetics in selenium-replete men', Oncotarget, vol. 8, no. 16, pp. 26312-26322. https://doi.org/10.18632/oncotarget.15460
Marshall, James R. ; Burk, Raymond F. ; Ondracek, Rochelle Payne ; Hill, Kristina E. ; Perloff, Marjorie ; Davis, Warren ; Pili, Roberto ; George, Saby ; Bergan, Raymond. / Selenomethionine and methyl selenocysteine : Multiple-dose pharmacokinetics in selenium-replete men. In: Oncotarget. 2017 ; Vol. 8, No. 16. pp. 26312-26322.
@article{a2d440d914ee401787748534ab3bf64f,
title = "Selenomethionine and methyl selenocysteine: Multiple-dose pharmacokinetics in selenium-replete men",
abstract = "According to the Nutritional Prevention of Cancer (NPC) trial, a selenized yeast supplement containing selenium, 200 mcg/day, decreased the incidence of total cancer, cancers of the prostate, colon and lung, and cancer mortality. The active agent in the selenized yeast supplement was assumed to be selenomethionine (SEMET), although the supplement had not been well speciated. The SELECT study, largely motivated by the NPC trial, enrolling nearly 40 times as many subjects, showed unequivocally that selenium 200 mcg/day, with selenium in the form of SEMET, does not protect selenium-replete men against prostate or other major cancer. The agent tested by SELECT, pure SEMET, could have been different from the selenized yeast tested in NPC. One of the selenium forms suspected of having chemopreventive effects, and which may have been present in the NPC agent, is methyl selenocysteine (MSC). This study, with 29 selenium-replete patients enrolled in a randomized, double-blind trial, compared the multiple-dose toxicity, pharmacokinetics and pharmacodynamics of MSC and SEMET. Patients were on trial for 84 days. No toxicity was observed. Although SEMET supplementation increased blood selenium concentration more than MSC did, neither form had a more than minimal impact on the two major selenoproteins: selenoprotein P(SEPP1) and glutathione peroxidase(GPX).",
keywords = "Chemoprevention, Methyl selenocysteine, Pharmacokinetics, Selenium, Selenomethionine",
author = "Marshall, {James R.} and Burk, {Raymond F.} and Ondracek, {Rochelle Payne} and Hill, {Kristina E.} and Marjorie Perloff and Warren Davis and Roberto Pili and Saby George and Raymond Bergan",
year = "2017",
doi = "10.18632/oncotarget.15460",
language = "English (US)",
volume = "8",
pages = "26312--26322",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "16",

}

TY - JOUR

T1 - Selenomethionine and methyl selenocysteine

T2 - Multiple-dose pharmacokinetics in selenium-replete men

AU - Marshall, James R.

AU - Burk, Raymond F.

AU - Ondracek, Rochelle Payne

AU - Hill, Kristina E.

AU - Perloff, Marjorie

AU - Davis, Warren

AU - Pili, Roberto

AU - George, Saby

AU - Bergan, Raymond

PY - 2017

Y1 - 2017

N2 - According to the Nutritional Prevention of Cancer (NPC) trial, a selenized yeast supplement containing selenium, 200 mcg/day, decreased the incidence of total cancer, cancers of the prostate, colon and lung, and cancer mortality. The active agent in the selenized yeast supplement was assumed to be selenomethionine (SEMET), although the supplement had not been well speciated. The SELECT study, largely motivated by the NPC trial, enrolling nearly 40 times as many subjects, showed unequivocally that selenium 200 mcg/day, with selenium in the form of SEMET, does not protect selenium-replete men against prostate or other major cancer. The agent tested by SELECT, pure SEMET, could have been different from the selenized yeast tested in NPC. One of the selenium forms suspected of having chemopreventive effects, and which may have been present in the NPC agent, is methyl selenocysteine (MSC). This study, with 29 selenium-replete patients enrolled in a randomized, double-blind trial, compared the multiple-dose toxicity, pharmacokinetics and pharmacodynamics of MSC and SEMET. Patients were on trial for 84 days. No toxicity was observed. Although SEMET supplementation increased blood selenium concentration more than MSC did, neither form had a more than minimal impact on the two major selenoproteins: selenoprotein P(SEPP1) and glutathione peroxidase(GPX).

AB - According to the Nutritional Prevention of Cancer (NPC) trial, a selenized yeast supplement containing selenium, 200 mcg/day, decreased the incidence of total cancer, cancers of the prostate, colon and lung, and cancer mortality. The active agent in the selenized yeast supplement was assumed to be selenomethionine (SEMET), although the supplement had not been well speciated. The SELECT study, largely motivated by the NPC trial, enrolling nearly 40 times as many subjects, showed unequivocally that selenium 200 mcg/day, with selenium in the form of SEMET, does not protect selenium-replete men against prostate or other major cancer. The agent tested by SELECT, pure SEMET, could have been different from the selenized yeast tested in NPC. One of the selenium forms suspected of having chemopreventive effects, and which may have been present in the NPC agent, is methyl selenocysteine (MSC). This study, with 29 selenium-replete patients enrolled in a randomized, double-blind trial, compared the multiple-dose toxicity, pharmacokinetics and pharmacodynamics of MSC and SEMET. Patients were on trial for 84 days. No toxicity was observed. Although SEMET supplementation increased blood selenium concentration more than MSC did, neither form had a more than minimal impact on the two major selenoproteins: selenoprotein P(SEPP1) and glutathione peroxidase(GPX).

KW - Chemoprevention

KW - Methyl selenocysteine

KW - Pharmacokinetics

KW - Selenium

KW - Selenomethionine

UR - http://www.scopus.com/inward/record.url?scp=85017516482&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017516482&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.15460

DO - 10.18632/oncotarget.15460

M3 - Article

VL - 8

SP - 26312

EP - 26322

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 16

ER -